Alamar Biosciences, Inc. is a commercial-stage proteomics company engaged in protein detection and analysis. The Company's proprietary NULISA (Nucleic Acid Linked Immuno-Sandwich Assay) technology addresses the limitations of existing proteomics tools by detecting protein biomarkers at extremely low concentrations in non-invasive biological fluids, such as blood, with ultra-high sensitivity, high specificity, flexible multiplexing, dynamic range and automation. Its integrated platform consists of proprietary instruments, consumables and analytical software that is designed to provide scientists with an end-to-end solution to precisely and consistently measure from one to hundreds of low-abundances and difficult-to-detect biomarkers across the continuum of discovery, translational research and ultimately diagnostics. Its instrument, the ARGO HT System, is designed to fully automate high-sensitivity and high-plex proteomics analysis and is available for research use only applications.
์ข
๋ชฉ ์ฝ๋ ALMR
ํ์ฌ ์ด๋ฆAlamar Biosciences Inc
์์ฅ์ผApr 17, 2026
CEOLuo (Yuling)
์ง์ ์- -
์ ํOrdinary Share
ํ๊ณ ์ฐ๋ ์ข
๋ฃ- -
์ฃผ์47071 Bayside Pkwy
๋์FREMONT
์ฆ๊ถ ๊ฑฐ๋์NASDAQ OMX - NASDAQ BASIC
๊ตญ๊ฐUnited States of America
์ฐํธ ๋ฒํธ94538
์ ํ15106269888
์น์ฌ์ดํธhttps://alamarbio.com
์ข
๋ชฉ ์ฝ๋ ALMR
์์ฅ์ผApr 17, 2026
CEOLuo (Yuling)